Lenvatinib (BioDeep_00000858595)
代谢物信息卡片
Lenvatinib (E7080)
化学式: C21H19ClN4O4 (426.10947640000006)
中文名称: 乐伐替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl
InChI: InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
D000970 - Antineoplastic Agents
同义名列表
2 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:85994
- KEGGdrug: D09919
- PubChem: 9823820
- DrugBank: DB09078
- ChEMBL: CHEMBL1289601
- CAS: 417716-92-8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Han Zhao, Wenyan Kang, Jian Guan, Ying Wang. Palliative treatment of generalized metastatic follicular carcinoma of thyroid after operation: A case report and literature review.
Medicine.
2024 May; 103(20):e38237. doi:
10.1097/md.0000000000038237. [PMID: 38758843] - Jing Zhao, Dongming Yan, Yue Li, Xiaoqing Xu, Fengling Li, Shuang Zhang, Jingyi Jin, Furong Qiu. Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2024 Apr; 1237(?):124100. doi:
10.1016/j.jchromb.2024.124100. [PMID: 38547701] - Hiroyuki Suzuki, Hideki Iwamoto, Toshimitsu Tanaka, Takahiko Sakaue, Yasuko Imamura, Atsutaka Masuda, Toru Nakamura, Hironori Koga, Yujin Hoshida, Takumi Kawaguchi. Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma.
Hepatology international.
2024 Apr; 18(2):610-622. doi:
10.1007/s12072-023-10603-z. [PMID: 37864726] - Zhong-Chen Li, Jie Wang, He-Bin Liu, Yi-Min Zheng, Jian-Hang Huang, Jia-Bin Cai, Lei Zhang, Xin Liu, Ling Du, Xue-Ting Yang, Xiao-Qiang Chai, Ying-Hua Jiang, Zheng-Gang Ren, Jian Zhou, Jia Fan, De-Cai Yu, Hui-Chuan Sun, Cheng Huang, Feng Liu. Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-PD1 therapy.
Cell reports.
2024 Mar; 43(3):113877. doi:
10.1016/j.celrep.2024.113877. [PMID: 38421869] - Xianhua She, Donghong Yin, Qian Guo, Yang Tang, Shuyun Wang, Xuyan Wang. Electrolyte disorders induced by six multikinase inhibitors therapy for renal cell carcinoma: a large-scale pharmacovigilance analysis.
Scientific reports.
2024 03; 14(1):5592. doi:
10.1038/s41598-024-56335-4. [PMID: 38454105] - Xinyue Zhang, Tianhong Su, Yifan Wu, Yuhong Cai, Lina Wang, Cong Liang, Lei Zhou, Shiyan Wang, Xiao-Xing Li, Sui Peng, Ming Kuang, Jun Yu, Lixia Xu. N6-methyladenosine reader YTHDF1 promotes stemness and therapeutic resistance in hepatocellular carcinoma by enhancing NOTCH1 expression.
Cancer research.
2024 Jan; ?(?):. doi:
10.1158/0008-5472.can-23-1916. [PMID: 38241695] - Mianmian Liao, Meirong Qin, Linhua Liu, Houshuang Huang, Ning Chen, Haiyan Du, Danping Huang, Ping Wang, Hua Zhou, Guangdong Tong. Exosomal microRNA profiling revealed enhanced autophagy suppression and anti-tumor effects of a combination of compound Phyllanthus urinaria and lenvatinib in hepatocellular carcinoma.
Phytomedicine : international journal of phytotherapy and phytopharmacology.
2024 Jan; 122(?):155091. doi:
10.1016/j.phymed.2023.155091. [PMID: 37844378] - Wenyun Guo, Songling Li, Yifei Qian, Linfeng Li, Fan Wang, Yu Tong, Qianyu Li, Zijun Zhu, Wei-Qiang Gao, Yanfeng Liu. KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression.
Clinical and translational medicine.
2023 10; 13(10):e1452. doi:
10.1002/ctm2.1452. [PMID: 37846441] - Yizhe Cheng, Ping Zhan, Jing Lu, Yuyan Lu, Changhong Luo, Xuesong Cen, Fuqiang Wang, Chengrong Xie, Zhenyu Yin. Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT-FOXO3 signalling pathway.
Liver international : official journal of the International Association for the Study of the Liver.
2023 May; ?(?):. doi:
10.1111/liv.15611. [PMID: 37208925] - Jingyang Su, Yue Fu, Menglei Wang, Shengyou Lin. Reply: Clinical efficacy of lenvatinib for the treatment of radioiodine-refractory thyroid carcinoma: A systematic review and meta-analysis of clinical trials.
Clinical endocrinology.
2023 02; 98(2):275-276. doi:
10.1111/cen.14718. [PMID: 35261050] - Long Yang, Pinsheng Han, Tao Cui, Yu Miao, Tianyu Zhao, Zilin Cui, Yijia Chen, Hao Chi, Jieying Zhang, Yamin Zhang. M2 macrophage inhibits the antitumor effects of Lenvatinib on intrahepatic cholangiocarcinoma.
Frontiers in immunology.
2023; 14(?):1251648. doi:
10.3389/fimmu.2023.1251648. [PMID: 37809069] - Yufeng Liu, Linmao Sun, Hongrui Guo, Shuo Zhou, Chunxu Wang, Changyong Ji, Fanzheng Meng, Shuhang Liang, Bo Zhang, Yubin Yuan, Kun Ma, Xianying Li, Xinyu Guo, Tianming Cui, Ning Zhang, Jiabei Wang, Yao Liu, Lianxin Liu. Targeting SLP2-mediated lipid metabolism reprograming restricts proliferation and metastasis of hepatocellular carcinoma and promotes sensitivity to Lenvatinib.
Oncogene.
2023 01; 42(5):374-388. doi:
10.1038/s41388-022-02551-z. [PMID: 36473908] - Chen Liang, Di Zhu, Wei Xia, Zi Hong, Qiu-Shi Wang, Yu Sun, Yan-Chao Yang, Song-Qi Han, Liang-Liang Tang, Jie Lou, Ming-Ming Wu, Zhi-Ren Zhang. Inhibition of YAP by lenvatinib in endothelial cells increases blood pressure through ferroptosis.
Biochimica et biophysica acta. Molecular basis of disease.
2023 01; 1869(1):166586. doi:
10.1016/j.bbadis.2022.166586. [PMID: 36374802] - Beiyuan Hu, Tiantian Zou, Wei Qin, Xiaotian Shen, Yinghan Su, Jianhua Li, Yang Chen, Ze Zhang, Haoting Sun, Yan Zheng, Chao-Qun Wang, Zhengxin Wang, Tian-En Li, Shun Wang, Le Zhu, Xufeng Wang, Yan Fu, Xudong Ren, Qiongzhu Dong, Lun-Xiu Qin. Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma.
Cancer research.
2022 10; 82(20):3845-3857. doi:
10.1158/0008-5472.can-21-4140. [PMID: 36066408] - Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Atsushi Naganuma, Tomoko Aoki, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Yoichi Hiasa, Masatoshi Kudo. Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis.
European journal of gastroenterology & hepatology.
2022 Aug; 34(8):857-864. doi:
10.1097/meg.0000000000002398. [PMID: 35802527] - Xiang Dong, Zewu Zhang, Qin Zhang, Lu Chen, Guangtai Cao, Chen Liu, Tianqiang Song, Wei Lu, Wei Zhang. Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy.
Journal of cancer research and clinical oncology.
2022 Jul; ?(?):. doi:
10.1007/s00432-022-04166-z. [PMID: 35802197] - Norifumi Iseda, Shinji Itoh, Katsuya Toshida, Takahiro Tomiyama, Akinari Morinaga, Masahiro Shimokawa, Tomonari Shimagaki, Huanlin Wang, Takeshi Kurihara, Takeo Toshima, Yoshihiro Nagao, Noboru Harada, Tomoharu Yoshizumi, Masaki Mori. Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma.
Cancer science.
2022 Jul; 113(7):2272-2287. doi:
10.1111/cas.15378. [PMID: 35466502] - Zhongnan Xu, Yanli Wang, Guangwen Liu, Jiahui Chen, Wanhua Wang, Yang Cheng, Qing Ren, Yingzi Cui, Wei Yang, Zhengzhi Liu, Xuesong Chen, Jinling Xue, Tianying Chang, Xinyao Qu, Shuang Yu, Yannan Zhou, Kaibo Xu, Zhengjie Su, Qiaohuan Deng, Yicheng Zhao, Haimiao Yang. A randomized, open-label, single-dose, two-cycle crossover study to evaluate the bioequivalence and safety of lenvatinib and Lenvima® in Chinese healthy subjects.
Expert opinion on investigational drugs.
2022 Jul; 31(7):737-746. doi:
10.1080/13543784.2022.2067528. [PMID: 35427205] - Arnaud Saillant, Delphine Borchiellini. [New drug approval: Lenvatinib plus pembrolizumab for advanced renal cell carcinoma].
Bulletin du cancer.
2022 Jul; 109(7-8):737-738. doi:
10.1016/j.bulcan.2022.03.008. [PMID: 35599170] - Robert Motzer, Camillo Porta, Boris Alekseev, Sun Young Rha, Toni K Choueiri, Maria Jose Mendez-Vidal, Sung-Hoo Hong, Anil Kapoor, Jeffrey C Goh, Masatoshi Eto, Lee Bennett, Jinyi Wang, Jie Janice Pan, Todd L Saretsky, Rodolfo F Perini, Cixin Steven He, Kalgi Mody, David Cella. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
The Lancet. Oncology.
2022 06; 23(6):768-780. doi:
10.1016/s1470-2045(22)00212-1. [PMID: 35489363] - Ryu Sasaki, Masanori Fukushima, Masafumi Haraguchi, Takuya Honda, Satoshi Miuma, Hisamitsu Miyaaki, Kazuhiko Nakao. Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma.
Medicine.
2022 May; 101(19):e29289. doi:
10.1097/md.0000000000029289. [PMID: 35583540] - Robert J Motzer, Matthew H Taylor, Thomas R Jeffry Evans, Takuji Okusaka, Hilary Glen, Gregory M Lubiniecki, Corina Dutcus, Alan D Smith, Chinyere E Okpara, Ziad Hussein, Seiichi Hayato, Toshiyuki Tamai, Vicky Makker. Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.
Expert review of anticancer therapy.
2022 04; 22(4):383-400. doi:
10.1080/14737140.2022.2039123. [PMID: 35260027] - Yanjun Cui, Ying Li, Xiao Li, Liju Fan, Xueru He, Yuhao Fu, Zhanjun Dong. A Simple UPLC/MS-MS Method for Simultaneous Determination of Lenvatinib and Telmisartan in Rat Plasma, and Its Application to Pharmacokinetic Drug-Drug Interaction Study.
Molecules (Basel, Switzerland).
2022 Feb; 27(4):. doi:
10.3390/molecules27041291. [PMID: 35209080] - Marco Delsante, Jose M Monroy-Trujillo, Naima Carter-Monroe, Douglas W Ball, Avi Z Rosenberg. Lenvatinib-related renal microangiopathy: a case series.
Virchows Archiv : an international journal of pathology.
2022 Feb; 480(2):467-473. doi:
10.1007/s00428-021-03114-5. [PMID: 33959820] - Yusuke Adachi, Hiroshi Kamiyama, Kenji Ichikawa, Sayo Fukushima, Yoichi Ozawa, Shogo Yamaguchi, Satoshi Goda, Takayuki Kimura, Kotaro Kodama, Masahiro Matsuki, Saori Watanabe Miyano, Akira Yokoi, Yu Kato, Yasuhiro Funahashi. Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies.
Cancer research.
2022 01; 82(2):292-306. doi:
10.1158/0008-5472.can-20-2426. [PMID: 34753772] - Matteo Santoni, Alessandro Rizzo, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Benedetta Fragomeno, Nicola Battelli, Francesco Massari. Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis.
Expert review of pharmacoeconomics & outcomes research.
2022 Jan; 22(1):45-51. doi:
10.1080/14737167.2021.1937130. [PMID: 34058953] - Hironao Okubo, Hitoshi Ando, Eisuke Nakadera, Kenichi Ikejima, Shuichiro Shiina, Akihito Nagahara. Levocarnitine Supplementation Suppresses Lenvatinib-Related Sarcopenia in Hepatocellular Carcinoma Patients: Results of a Propensity Score Analysis.
Nutrients.
2021 Dec; 13(12):. doi:
10.3390/nu13124428. [PMID: 34959980] - Haojing Song, Wanjun Bai, Xue Sun, Bo Qiu, Nini Guo, Caihui Guo, Yiting Hu, Zhanjun Dong. Association between pharmacokinetics of lenvatinib in healthy subjects and genetic polymorphisms of ABCB1 3435C>T and ABCB1 2677G>T/A.
Xenobiotica; the fate of foreign compounds in biological systems.
2021 Dec; 51(12):1463-1469. doi:
10.1080/00498254.2021.2023913. [PMID: 34979850] - Nicholas J Vogelzang, Alisha M Monnette, Yunfei Wang, Yin Wan, Yiqiong Xie, Nicholas J Robert, Nizar M Tannir. Real-world Clinical Effectiveness of Lenvatinib/Everolimus in a Heavily Pretreated Advanced/Metastatic Renal Cell Carcinoma Population in the US Community Oncology Setting.
Clinical genitourinary cancer.
2021 12; 19(6):531-539. doi:
10.1016/j.clgc.2021.05.002. [PMID: 34112611] - Mengmeng Lu, Xiaokang Zhang, Xiaoge Gao, Shishuo Sun, Xiaohuan Wei, Xiaolei Hu, Chao Huang, Heng Xu, Bixi Wang, Wei Zhang, Zhen Li, Xinhui Feng, Junnian Zheng, Qing Zhang. Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer.
Pharmacological research.
2021 12; 174(?):105829. doi:
10.1016/j.phrs.2021.105829. [PMID: 34411731] - Yanjun Cui, Ying Li, Liju Fan, Jing An, Xiaonan Wang, Ran Fu, Zhanjun Dong. UPLC-MS/MS method for the determination of Lenvatinib in rat plasma and its application to drug-drug interaction studies.
Journal of pharmaceutical and biomedical analysis.
2021 Nov; 206(?):114360. doi:
10.1016/j.jpba.2021.114360. [PMID: 34508926] - Junichi Shindoh, Yusuke Kawamura, Yuta Kobayashi, Masahiro Kobayashi, Norio Akuta, Satoshi Okubo, Yoshiyuki Suzuki, Masaji Hashimoto. Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma.
Annals of surgical oncology.
2021 Nov; 28(12):7663-7672. doi:
10.1245/s10434-021-09974-0. [PMID: 33904001] - Pietro Locantore, Valeria Del Gatto, Andrea Corsello, Alfredo Pontecorvi. Lenvatinib treatment for thyroid cancer in COVID era: safety in a patient with lung metastases and SARS-CoV-2 infection.
Anti-cancer drugs.
2021 11; 32(10):1116-1117. doi:
10.1097/cad.0000000000001097. [PMID: 34183494] - Mabel Ryder, Mark Wentworth, Alicia Algeciras-Schimnich, John C Morris, James Garrity, Jane Sanders, Stuart Young, Paul Sanders, Jadwiga Furmaniak, Bernard Rees Smith. Blocking the Thyrotropin Receptor with K1-70 in a Patient with Follicular Thyroid Cancer, Graves' Disease, and Graves' Ophthalmopathy.
Thyroid : official journal of the American Thyroid Association.
2021 10; 31(10):1597-1602. doi:
10.1089/thy.2021.0053. [PMID: 34114495] - Yoshio Sueshige, Ken Shiraiwa, Koichi Honda, Ryota Tanaka, Tomoko Saito, Masanori Tokoro, Masao Iwao, Mizuki Endo, Mie Arakawa, Ryosuke Tatsuta, Masataka Seike, Kazunari Murakami, Hiroki Itoh. A Broad Range High-Throughput Assay for Lenvatinib Using Ultra-High Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry With Clinical Application in Patients With Hepatocellular Carcinoma.
Therapeutic drug monitoring.
2021 10; 43(5):664-671. doi:
10.1097/ftd.0000000000000872. [PMID: 34521802] - Richard S Finn, Masatoshi Kudo, Ann-Lii Cheng, Lucjan Wyrwicz, Roger K C Ngan, Jean-Frederic Blanc, Ari D Baron, Arndt Vogel, Masafumi Ikeda, Fabio Piscaglia, Kwang-Hyub Han, Shukui Qin, Yukinori Minoshima, Michio Kanekiyo, Min Ren, Ryo Dairiki, Toshiyuki Tamai, Corina E Dutcus, Hiroki Ikezawa, Yasuhiro Funahashi, Thomas R Jeffry Evans. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2021 09; 27(17):4848-4858. doi:
10.1158/1078-0432.ccr-20-4219. [PMID: 34108184] - Chung-Han Lee, Renzo G DiNatale, Diego Chowell, Chirag Krishna, Vladimir Makarov, Cristina Valero, Lynda Vuong, Mark Lee, Kate Weiss, Doug Hoen, Luc Morris, Ed Reznik, Samuel Murray, Ritesh Kotecha, Martin H Voss, Maria I Carlo, Darren Feldman, Pallavi Sachdev, Yusuke Adachi, Yukinori Minoshima, Junji Matsui, Yasuhiro Funahashi, Kenichi Nomoto, A Ari Hakimi, Robert J Motzer, Timothy A Chan. High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.
Molecular cancer research : MCR.
2021 09; 19(9):1510-1521. doi:
10.1158/1541-7786.mcr-21-0053. [PMID: 34039647] - Hisanori Muto, Teiji Kuzuya, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Masatoshi Ishigami, Mitsuhiro Fujishiro. Transient deterioration of albumin-bilirubin scores in early post-dose period of molecular targeted therapies in advanced hepatocellular carcinoma with 50\% or higher liver occupation: A STROBE-compliant retrospective observational study.
Medicine.
2021 Aug; 100(31):e26820. doi:
10.1097/md.0000000000026820. [PMID: 34397843] - Zhenjie Ye, Lingjie Wu, Xiaoying Zhang, Yingying Hu, Ling Zheng. Quantification of sorafenib, lenvatinib, and apatinib in human plasma for therapeutic drug monitoring by UPLC-MS/MS.
Journal of pharmaceutical and biomedical analysis.
2021 Aug; 202(?):114161. doi:
10.1016/j.jpba.2021.114161. [PMID: 34052550] - Chie Masaki, Kiminori Sugino, Sakiko Kobayashi, Yoshie Hosoi, Reiko Ono, Haruhiko Yamazaki, Junko Akaishi, Kiyomi Y Hames, Chisato Tomoda, Akifumi Suzuki, Kenichi Matsuzu, Keiko Ohkuwa, Wataru Kitagawa, Mitsuji Nagahama, Koichi Ito. Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients.
BMC cancer.
2021 Aug; 21(1):894. doi:
10.1186/s12885-021-08622-w. [PMID: 34353305] - Thomas E Hutson, M Dror Michaelson, Timothy M Kuzel, Neeraj Agarwal, Ana M Molina, James J Hsieh, Ulka N Vaishampayan, Ran Xie, Urmi Bapat, Weifei Ye, Rohit K Jain, Mayer N Fishman. A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma.
European urology.
2021 08; 80(2):162-170. doi:
10.1016/j.eururo.2021.03.015. [PMID: 33867192] - Elif Hindié. Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma.
The New England journal of medicine.
2021 07; 385(3):287. doi:
10.1056/nejmc2107518. [PMID: 34260845] - Robert Motzer, Toni K Choueiri. Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma. Reply.
The New England journal of medicine.
2021 07; 385(3):287. doi:
10.1056/nejmc2107518. [PMID: 34260846] - Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Shinya Fukunishi, Hideko Ohama, Kazuhito Kawata, Joji Tani, Shinichiro Nakamura, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Tanaka Takaaki, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Kouji Joko, Yohei Koizumi, Yoichi Hiasa. Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib.
Scientific reports.
2021 07; 11(1):14474. doi:
10.1038/s41598-021-93794-5. [PMID: 34262065] - Marie O Pohl, Idoia Busnadiego, Francesco Marrafino, Lars Wiedmer, Annika Hunziker, Sonja Fernbach, Irina Glas, Elena V Moroz-Omori, Benjamin G Hale, Amedeo Caflisch, Silke Stertz. Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir.
The Journal of general virology.
2021 07; 102(7):. doi:
10.1099/jgv.0.001625. [PMID: 34319869] - Chung-Han Lee, Amishi Yogesh Shah, Drew Rasco, Arpit Rao, Matthew H Taylor, Christopher Di Simone, James J Hsieh, Alvaro Pinto, David R Shaffer, Regina Girones Sarrio, Allen Lee Cohn, Nicholas J Vogelzang, Mehmet Asim Bilen, Sara Gunnestad Ribe, Musaberk Goksel, Øyvind Krohn Tennøe, Donald Richards, Randy F Sweis, Jay Courtright, Daniel Heinrich, Sharad Jain, Jane Wu, Emmett V Schmidt, Rodolfo F Perini, Peter Kubiak, Chinyere E Okpara, Alan D Smith, Robert J Motzer. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
The Lancet. Oncology.
2021 07; 22(7):946-958. doi:
10.1016/s1470-2045(21)00241-2. [PMID: 34143969] - Yasutoshi Fujii, Atsushi Ono, C Nelson Hayes, Hiroshi Aikata, Masami Yamauchi, Shinsuke Uchikawa, Kenichiro Kodama, Yuji Teraoka, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Daiki Miki, Wataru Okamoto, Tomokazu Kawaoka, Masataka Tsuge, Michio Imamura, Kazuaki Chayama. Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib.
Journal of experimental & clinical cancer research : CR.
2021 Jun; 40(1):215. doi:
10.1186/s13046-021-02016-3. [PMID: 34174931] - Andrew J Wiele, Tharakeswara K Bathala, Andrew W Hahn, Lianchun Xiao, Munevver Duran, Jeremy A Ross, Eric Jonasch, Amishi Y Shah, Matthew T Campbell, Pavlos Msaouel, Nizar M Tannir. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
The oncologist.
2021 06; 26(6):476-482. doi:
10.1002/onco.13770. [PMID: 33792094] - Yu-Chang Liu, Fei-Ting Hsu, Jing-Gung Chung, Mao-Chi Weng, Chien-Yi Ting, Chia-Jung Tsai, Alexander Lan, Jeng-Yuan Wu, Charles Chung-Wei Lin, Song-Shei Lin. Lenvatinib Induces AKT/NF-κB Inactivation, Apoptosis Signal Transduction and Growth Inhibition of Non-small Cell Lung Cancer In Vivo.
Anticancer research.
2021 Jun; 41(6):2867-2874. doi:
10.21873/anticanres.15068. [PMID: 34083277] - Dan Liu, Lei Liu, Lin Shen, Tomoki Kubota, Takuya Suzuki, Hiroki Ikezawa, Sari Shiba, Yuxian Bai. Pharmacokinetic study of lenvatinib in Chinese patients with solid tumors.
Future oncology (London, England).
2021 May; 17(15):1855-1863. doi:
10.2217/fon-2020-0877. [PMID: 33474967] - Shuangshuang Zhang, Ludan Zhao, Xu Peng, Qiaomei Sun, Xiaoxiang Liao, Na Gan, Gang Zhao, Hui Li. Self-assembled phospholipid-based mixed micelles for improving the solubility, bioavailability and anticancer activity of lenvatinib.
Colloids and surfaces. B, Biointerfaces.
2021 May; 201(?):111644. doi:
10.1016/j.colsurfb.2021.111644. [PMID: 33639512] - Takuma Izutsu, Hiroyuki Ito, Izumi Fukuda, Hideki Tamura, Suzuko Matsumoto, Shinichi Antoku, Toshiko Mori, Hiroaki Goto. Early Improvement of Non-islet Cell Tumor Hypoglycemia by Chemotherapy Using Lenvatinib in a Case with Type 2 Diabetes and Hepatocellular Carcinoma Producing Big IGF-II.
Internal medicine (Tokyo, Japan).
2021 May; 60(9):1427-1432. doi:
10.2169/internalmedicine.5328-20. [PMID: 33250459] - Alain Ravaud. A Step Ahead in Metastatic Renal Cell Carcinoma.
The New England journal of medicine.
2021 04; 384(14):1360-1361. doi:
10.1056/nejme2101777. [PMID: 33616313] - Robert Motzer, Boris Alekseev, Sun-Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E Hutson, Evgeny Kopyltsov, María J Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung-Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R Merchan, Eric Winquist, Pablo Maroto, Jeffrey C Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frederic Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E Dutcus, Alan D Smith, Lea Dutta, Kalgi Mody, Rodolfo F Perini, Dongyuan Xing, Toni K Choueiri. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
The New England journal of medicine.
2021 04; 384(14):1289-1300. doi:
10.1056/nejmoa2035716. [PMID: 33616314] - Tian Zhang, Daniel J George. Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment.
Nature medicine.
2021 04; 27(4):586-588. doi:
10.1038/s41591-021-01320-x. [PMID: 33820997] - Allen Jacob, Jaret Shook, Thomas Hutson. The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma.
Expert review of anticancer therapy.
2021 04; 21(4):365-372. doi:
10.1080/14737140.2021.1868994. [PMID: 33393393] - Andrew L Laccetti, Benjamin Garmezy, Lianchun Xiao, Minas Economides, Aradhana Venkatesan, Jianjun Gao, Eric Jonasch, Paul Corn, Amado Zurita-Saavedra, Landon C Brown, Chester Kao, Emily N Kinsey, Rajan T Gupta, Michael R Harrison, Andrew J Armstrong, Daniel J George, Nizar Tannir, Pavlos Msaouel, Amishi Shah, Tian Zhang, Matthew T Campbell. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
Cancer medicine.
2021 04; 10(7):2341-2349. doi:
10.1002/cam4.3812. [PMID: 33650321] - Hiroaki Kanzaki, Tetsuhiro Chiba, Junjie Ao, Keisuke Koroki, Kengo Kanayama, Susumu Maruta, Takahiro Maeda, Yuko Kusakabe, Kazufumi Kobayashi, Naoya Kanogawa, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Tomoko Saito, Ryo Nakagawa, Sadahisa Ogasawara, Eiichiro Suzuki, Yoshihiko Ooka, Ryosuke Muroyama, Shingo Nakamoto, Shin Yasui, Akinobu Tawada, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Naoya Mimura, Jun Kato, Yoh Zen, Masayuki Ohtsuka, Atsushi Iwama, Naoya Kato. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.
Scientific reports.
2021 03; 11(1):5303. doi:
10.1038/s41598-021-84117-9. [PMID: 33674622] - Yuki Otani, Hidefumi Kasai, Yusuke Tanigawara. Pharmacodynamic analysis of hypertension caused by lenvatinib using real-world postmarketing surveillance data.
CPT: pharmacometrics & systems pharmacology.
2021 03; 10(3):188-198. doi:
10.1002/psp4.12587. [PMID: 33471960] - Yuta Myojin, Takahiro Kodama, Kazuki Maesaka, Daisuke Motooka, Yu Sato, Satoshi Tanaka, Yuichi Abe, Kazuyoshi Ohkawa, Eiji Mita, Yoshito Hayashi, Hayato Hikita, Ryotaro Sakamori, Tomohide Tatsumi, Ayumu Taguchi, Hidetoshi Eguchi, Tetsuo Takehara. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2021 02; 27(4):1150-1161. doi:
10.1158/1078-0432.ccr-20-3382. [PMID: 33288659] - Martina Zanchetta, Valentina Iacuzzi, Bianca Posocco, Giorgia Bortolin, Ariana Soledad Poetto, Marco Orleni, Giovanni Canil, Michela Guardascione, Luisa Foltran, Valentina Fanotto, Fabio Puglisi, Sara Gagno, Giuseppe Toffoli. A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring.
PloS one.
2021; 16(10):e0259137. doi:
10.1371/journal.pone.0259137. [PMID: 34699578] - Taku Shigesawa, Goki Suda, Megumi Kimura, Osamu Maehara, Yoshimasa Tokuchi, Akinori Kubo, Ren Yamada, Ken Furuya, Masaru Baba, Takashi Kitagataya, Kazuharu Suzuki, Masatsugu Ohara, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto. Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma.
PloS one.
2021; 16(3):e0247728. doi:
10.1371/journal.pone.0247728. [PMID: 33647018] - Chung-Han Lee, Robert J Motzer, Hilary Glen, M D Michaelson, James Larkin, Yukinori Minoshima, Michio Kanekiyo, Hiroki Ikezawa, Pallavi Sachdev, Corina E Dutcus, Yasuhiro Funahashi, Martin H Voss. Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma.
British journal of cancer.
2021 01; 124(1):237-246. doi:
10.1038/s41416-020-01092-0. [PMID: 33024271] - T Hatanaka, S Kakizaki, T Nagashima, T Ueno, M Namikawa, H Tojima, D Takizawa, A Naganuma, H Arai, K Sato, N Harimoto, K Shirabe, T Uraoka. A change in the timing for starting systemic therapies for hepatocellular carcinoma: the comparison of sorafenib and lenvatinib as the first-line treatment.
Acta gastro-enterologica Belgica.
2021 Jan; 84(1):65-72. doi:
10.51821/84.1.109. [PMID: 33639695] - Ke Wang, Haoyang Wang, Yan Lv, Huiling Liu, Jiabin Liu, Ying Zhang. Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis: a case report.
Annals of palliative medicine.
2021 Jan; 10(1):803-809. doi:
10.21037/apm-20-2572. [PMID: 33545802] - Xin Li, Jiahua Xu, Xiaoqiang Gu, Ling Chen, Qing Wu, Hongwei Li, Haoran Bai, Jinzu Yang, Jianxin Qian. Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma.
Frontiers in immunology.
2021; 12(?):740790. doi:
10.3389/fimmu.2021.740790. [PMID: 34733279] - Kojiro Hata, Kimitaka Suetsugu, Nobuaki Egashira, Yoko Makihara, Shinji Itoh, Tomoharu Yoshizumi, Masatake Tanaka, Motoyuki Kohjima, Hiroyuki Watanabe, Satohiro Masuda, Ichiro Ieiri. Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma.
Cancer chemotherapy and pharmacology.
2020 12; 86(6):803-813. doi:
10.1007/s00280-020-04178-x. [PMID: 33095285] - Teresa Zielli, Letizia Gnetti, Sebastiano Buti. Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case report.
Tumori.
2020 Dec; 106(6):NP79-NP83. doi:
10.1177/0300891620924472. [PMID: 32458743] - Ryoichi Narita, Kazuhiro Kotoh, Akitoshi Yoneda, Mitsuteru Motomura, Masaru Harada. Factors Raising Serum Ammonia Level During Lenvatinib Treatment of Patients With Hepatocellular Carcinoma.
Anticancer research.
2020 Sep; 40(9):5271-5276. doi:
10.21873/anticanres.14531. [PMID: 32878816] - Dong-Xu Wang, Xu Yang, Jian-Zhen Lin, Yi Bai, Jun-Yu Long, Xiao-Bo Yang, Samuel Seery, Hai-Tao Zhao. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China.
World journal of gastroenterology.
2020 Aug; 26(30):4465-4478. doi:
10.3748/wjg.v26.i30.4465. [PMID: 32874058] - Gianluca Perego, Paolo Barzaghi, Ivano Vavassori, Fausto Petrelli. Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy.
Medical oncology (Northwood, London, England).
2020 Aug; 37(9):81. doi:
10.1007/s12032-020-01408-3. [PMID: 32767163] - Jiaming Li, Xiaoqian Wang, Chen Ning, Zhaoyu Wang, Yao Wang, Ming Zheng, Siliang Zhang, Yang Lu, Yongjie Zhang, Ning Li, Xijing Chen, Di Zhao. Influences of ABC transporter and CYP3A4/5 genetic polymorphisms on the pharmacokinetics of lenvatinib in Chinese healthy subjects.
European journal of clinical pharmacology.
2020 Aug; 76(8):1125-1133. doi:
10.1007/s00228-020-02879-z. [PMID: 32382947] - Yusuke Watanabe, Kosuke Doki, Ikuo Sekine, Hisato Hara, Masato Homma. High-Performance Liquid Chromatography for Therapeutic Drug Monitoring of Serum Lenvatinib.
Therapeutic drug monitoring.
2020 08; 42(4):554-558. doi:
10.1097/ftd.0000000000000770. [PMID: 32398418] - Lana Hamieh, Rachel L Beck, Valerie H Le, James J Hsieh. The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy.
Clinical genitourinary cancer.
2020 08; 18(4):252-257.e2. doi:
10.1016/j.clgc.2020.03.003. [PMID: 32291161] - Chie Masaki, Kiminori Sugino, Sakiko Kobayashi, Junko Akaishi, Kiyomi Y Hames, Chisato Tomoda, Akifumi Suzuki, Kenichi Matsuzu, Takashi Uruno, Keiko Ohkuwa, Wataru Kitagawa, Mitsuji Nagahama, Koichi Ito. Urinalysis by combination of the dipstick test and urine protein-creatinine ratio (UPCR) assessment can prevent unnecessary lenvatinib interruption in patients with thyroid cancer.
International journal of clinical oncology.
2020 Jul; 25(7):1278-1284. doi:
10.1007/s10147-020-01678-x. [PMID: 32347432] - Matthew H Taylor, Chung-Han Lee, Vicky Makker, Drew Rasco, Corina E Dutcus, Jane Wu, Daniel E Stepan, Robert C Shumaker, Robert J Motzer. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2020 04; 38(11):1154-1163. doi:
10.1200/jco.19.01598. [PMID: 31961766] - Stefano Fogli, Camillo Porta, Marzia Del Re, Stefania Crucitta, Giulia Gianfilippo, Romano Danesi, Brian I Rini, Manuela Schmidinger. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.
Cancer treatment reviews.
2020 Mar; 84(?):101966. doi:
10.1016/j.ctrv.2020.101966. [PMID: 32044644] - Ignace Vergote, Matthew A Powell, Michael G Teneriello, David S Miller, Agustin A Garcia, Olga N Mikheeva, Mariusz Bidzinski, Cristina Ligia Cebotaru, Corina E Dutcus, Min Ren, Tadashi Kadowaki, Yasuhiro Funahashi, Richard T Penson. Second-line lenvatinib in patients with recurrent endometrial cancer.
Gynecologic oncology.
2020 03; 156(3):575-582. doi:
10.1016/j.ygyno.2019.12.039. [PMID: 31955859] - Shuya Honda, Yoshinori Saito, Koji Sawada, Takumu Hasebe, Shunsuke Nakajima, Toshikatsu Okumura. Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib.
Internal medicine (Tokyo, Japan).
2020 Mar; 59(5):657-662. doi:
10.2169/internalmedicine.3806-19. [PMID: 31735795] - Zhonglin Hao, Peng Wang. Lenvatinib in Management of Solid Tumors.
The oncologist.
2020 02; 25(2):e302-e310. doi:
10.1634/theoncologist.2019-0407. [PMID: 32043789] - Hironao Okubo, Hitoshi Ando, Kei Ishizuka, Ryuta Kitagawa, Shoki Okubo, Hiroaki Saito, Shigehiro Kokubu, Akihisa Miyazaki, Kenichi Ikejima, Shuichiro Shiina, Akihito Nagahara. Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma.
PloS one.
2020; 15(3):e0229772. doi:
10.1371/journal.pone.0229772. [PMID: 32126131] - Yasuyuki Tamai, Motoh Iwasa, Akiko Eguchi, Ryuta Shigefuku, Kazushi Sugimoto, Hiroshi Hasegawa, Yoshiyuki Takei. Serum copper, zinc and metallothionein serve as potential biomarkers for hepatocellular carcinoma.
PloS one.
2020; 15(8):e0237370. doi:
10.1371/journal.pone.0237370. [PMID: 32857769] - Tsuguru Hayashi, Michihiko Shibata, Shinji Oe, Koichiro Miyagawa, Yuichi Honma, Masaru Harada. C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib.
PloS one.
2020; 15(12):e0244370. doi:
10.1371/journal.pone.0244370. [PMID: 33351844] - Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Shinya Fukunishi, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Kazuhito Kawata, Hidenori Toyoda, Hideko Ohama, Akemi Tsutsui, Norio Itokawa, Korenobu Hayama, Taeang Arai, Michitaka Imai, Shinichiro Nakamura, Kojiro Michitaka, Yoichi Hiasa, Masatoshi Kudo. Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
Oncology.
2020; 98(5):295-302. doi:
10.1159/000506293. [PMID: 32097925] - Akira Fuchigami, Yukinori Imai, Yoshihito Uchida, Hiroshi Uchiya, Yohei Fujii, Manabu Nakazawa, Satsuki Ando, Kayoko Sugawara, Nobuaki Nakayama, Tomoaki Tomiya, Satoshi Mochida. Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome.
PloS one.
2020; 15(4):e0231427. doi:
10.1371/journal.pone.0231427. [PMID: 32275701] - Shinsuke Uchikawa, Tomokazu Kawaoka, Yuwa Ando, Kenji Yamaoka, Yumi Kosaka, Yosuke Suehiro, Yasutoshi Fujii, Kei Morio, Takashi Nakahara, Eisuke Murakami, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Shoichi Takahashi, Kazuaki Chayama, Hiroshi Aikata. Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors.
Oncology.
2020; 98(10):727-733. doi:
10.1159/000507815. [PMID: 32712613] - Hideo Kunimoto, Satoshi Shakado, Takashi Tanaka, Kazuhide Takata, Ryo Yamauchi, Hiromi Fukuda, Naoaki Tsuchiya, Keiji Yokoyama, Daisuke Morihara, Yasuaki Takeyama, Fumihito Hirai, Shotaro Sakisaka. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
Oncology.
2020; 98(11):779-786. doi:
10.1159/000509005. [PMID: 32877911] - Jee Hee Yoon, Min Ji Jeon, Mijin Kim, A Ram Hong, Hee Kyung Kim, Dong Yeob Shin, Bo Hyun Kim, Won Bae Kim, Young Kee Shong, Ho-Cheol Kang. Unusual metastases from differentiated thyroid cancers: A multicenter study in Korea.
PloS one.
2020; 15(8):e0238207. doi:
10.1371/journal.pone.0238207. [PMID: 32841270] - Kristie L Kahl. Novel Combination Shows Strong Antitumor Activity in Metastatic Renal Cell Carcinoma.
Oncology (Williston Park, N.Y.).
2019 Dec; 33(12):. doi:
NULL. [PMID: 31914201] - Hironobu Yagishita, Shinichiro Minami, Yumiko Akamine, Shotaro Kato, Katsunori Iijima, Masatomo Miura. Drug interactions between warfarin and lenvatinib in a patient with the CYP2C9*1/*3 and VKORC1-1639G/A genotype.
Journal of clinical pharmacy and therapeutics.
2019 Dec; 44(6):977-980. doi:
10.1111/jcpt.13030. [PMID: 31468576] - Hiroyuki Iwasaki, Haruhiko Yamazaki, Hirotaka Takasaki, Nobuyasu Suganuma, Rika Sakai, Hirotaka Nakayama, Soji Toda, Katsuhiko Masudo. Renal dysfunction in patients with radioactive iodine-refractory thyroid cancer treated with tyrosine kinase inhibitors: A retrospective study.
Medicine.
2019 Oct; 98(42):e17588. doi:
10.1097/md.0000000000017588. [PMID: 31626129] - Nanna Bæk Møller, Cecilie Budolfsen, Daniela Grimm, Marcus Krüger, Manfred Infanger, Markus Wehland, Nils E Magnusson. Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment.
International journal of molecular sciences.
2019 Sep; 20(19):. doi:
10.3390/ijms20194712. [PMID: 31547602] - Yuji Mano, Hitoshi Mizuo. Minimal impact of hepatic and renal impairment on plasma protein binding of lenvatinib, and identification of its major plasma binding protein.
Biopharmaceutics & drug disposition.
2019 Sep; 40(8):307-311. doi:
10.1002/bdd.2204. [PMID: 31426119] - Thomas R Jeffry Evans, Masatoshi Kudo, Richard S Finn, Kwang-Hyub Han, Ann-Lii Cheng, Masafumi Ikeda, Silvija Kraljevic, Min Ren, Corina E Dutcus, Fabio Piscaglia, Max W Sung. Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma.
British journal of cancer.
2019 07; 121(3):218-221. doi:
10.1038/s41416-019-0506-6. [PMID: 31249394] - Calvin Abro, Ramy Sedhom, Abha Soni, Mark Markowski. Cutaneous finger and tongue metastases in renal cell carcinoma.
BMJ case reports.
2019 Jun; 12(6):. doi:
10.1136/bcr-2019-230516. [PMID: 31229966] - Tomoko Ozeki, Mitsuji Nagahama, Kazuma Fujita, Akifumi Suzuki, Kiminori Sugino, Koichi Ito, Masatomo Miura. Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer.
Scientific reports.
2019 04; 9(1):5404. doi:
10.1038/s41598-019-41820-y. [PMID: 30931962] - Mitsuji Nagahama, Tomoko Ozeki, Akifumi Suzuki, Kiminori Sugino, Takenori Niioka, Koichi Ito, Masatomo Miura. Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer.
Medical oncology (Northwood, London, England).
2019 Mar; 36(5):39. doi:
10.1007/s12032-019-1263-3. [PMID: 30919115] - Viktor Grünwald, Thomas Powles, Toni K Choueiri, Thomas E Hutson, Camillo Porta, Masatoshi Eto, Cora N Sternberg, Sun Young Rha, Cixin S He, Corina E Dutcus, Alan Smith, Lea Dutta, Kalgi Mody, Robert J Motzer. Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.
Future oncology (London, England).
2019 Mar; 15(9):929-941. doi:
10.2217/fon-2018-0745. [PMID: 30689402] - Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Toshifumi Tada, Hidenori Toyoda, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Korenobu Hayama, Michitaka Imai, Kouji Joko, Yohei Koizumi, Yoichi Hiasa, Kojiro Michitaka. Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.
Oncology.
2019; 97(6):334-340. doi:
10.1159/000502095. [PMID: 31466068]